Fabry disease treatment market to surpass $3.5 billion


Selbyville, Delaware, Sept. 26, 2022 (GLOBE NEWSWIRE) —

Treatment of Fabry disease market value is expected to exceed $3.5 billion by 2030, according to a new research report from Global Market Insights Inc.

The growing emphasis on advancing genetic disease therapies will drive the expansion of the market. Several biotech companies have collaborated with healthcare organizations to design breakthrough disease treatment options. For example, 4D Molecular Therapeutics (4DMT) has partnered with the National Fabry Disease Foundation (NFDF) to develop advanced treatments for patients with Fabry disease.

Request a sample of this research report @ https://www.gminsights.com/request-sample/detail/4237

Attendants will become a key treatment option for patients with Fabry disease

The chaperone therapy segment accounted for 18% business share in 2021, given the growing awareness of the use of the active site-specific chaperone 1-deoxygalactonojirimycin. This therapy may facilitate the folding of mutant GLA (α-galactosidase A) into the endoplasmic reticulum and increase its residual lysosomal activity. Additionally, reduced Gb3 (globotriaosylceramide) deposition is shown in lymphoblasts from Fabry disease patients with a GLA missense mutation.

Browse key industry information spread over 109 pages with 123 market data tables and 17 report figures and graphs, “Fabry Disease Treatment Market Size by Treatment Type (Enzyme Replacement Therapy (ERT) {By Drug Type (Agalsidase Alpha, Agalsidase Beta}, End Use (Physician’s Office and Home Based)}, Chaperone Therapy) , Industry Analysis Report, Price Trends, Regional Outlook, Growth Potential, Competitive Market Share & Forecast, 2022-2030in detail with the table of contents:


Increase in the elderly population to support the development of the APAC industry

The Asia Pacific Fabry disease treatment market is poised to grow at a CAGR of over 10% through 2030, driven by the growing prevalence of the disease and awareness about its precise treatment. Due to the increasing complications associated with the disease and the need for accurate diagnosis and treatment, government agencies have also launched various initiatives. The report also reveals that the growing elderly population, which contributes to the target disease burden, will likely drive the expansion of Fabry disease treatment centers in the region.

Increase in product approvals by regulatory authorities to strengthen the industry landscape

Major players operating in the Fabry disease treatment market include Takeda, Sanofi, Amicus Therapeutics, ISU Abaxis, and JCR Pharmaceuticals Co Ltd, among other companies. These market players are rapidly developing innovative products with approval from various regulatory bodies.

Request to customize this research report @ https://www.gminsights.com/roc/4237

About Global Market Insights

Global Market Insights Inc., headquartered in Delaware, USA, is a global provider of market research and advisory services, offering syndicated and custom research reports as well as consulting services. growth. Our business intelligence and industry research reports provide clients with in-depth insights and actionable market data specially designed and presented to aid in strategic decision-making. These comprehensive reports are designed through proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy and biotechnology.


Comments are closed.